UBA2 and breast carcinoma: Moreover, data presented in this study provides proof-of-concept that SUMO pathway inhibition at the levels of E1 (SAE2) and E2 enzymes (UBC9) is sufficient to compromise cancer cell survival beyond breast cancer and lymphoma.